KRYS - Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
2024-07-30 23:13:17 ET
Summary
- Krystal Biotech's Q1 2024 revenue increased to $45.25 million but fell short of analyst expectations of $47.37 million. Analysts expect Q2 earnings to be $65.49 million.
- Vyjuvek's patient adherence rate dropped slightly to 91% in Q1 from 96% in the previous quarter.
- Krystal's pipeline, beyond dermatological and aesthetic pursuits, is pretty speculative and pursuing highly contested indications.
- I recommend a rating downgrade "hold" for Krystal due to its high valuation.
Krystal Biotech’s Vyjuvek: A Topical Triumph Driving Gains
Krystal Biotech's ( KRYS ) stock has risen another 25.6% since my previous "strong buy" recommendation in February....
Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)